{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:15:42Z","timestamp":1793121342783,"version":"4.5.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,15]]},"DOI":"10.2169\/internalmedicine.4037-24","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:10:48Z","timestamp":1723068648000},"page":"825-831","source":"Crossref","is-referenced-by-count":9,"title":["Real-world Efficacy of Erenumab on Migraine-associated Symptoms and Patient-reported Satisfaction Levels: A Retrospective Study in Japan"],"prefix":"10.2169","volume":"64","author":[{"given":"Keiko","family":"Ihara","sequence":"first","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"},{"name":"Japanese Red Cross Ashikaga Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"},{"name":"Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Tokuyasu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[{"name":"Division of Drug Informatics, Keio University Faculty of Pharmacy, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390: 1211-1259, 2017.","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"2","unstructured":"2. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17: 954-976, 2018."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17: 15-22, 1997.","DOI":"10.1046\/j.1468-2982.1997.1701015.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15: 382-390, 2016.","DOI":"10.1016\/S1474-4422(16)00019-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16: 425-434, 2017.","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 377: 2123-2132, 2017.","DOI":"10.1056\/NEJMoa1705848"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392: 2280-2287, 2018.","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Sakai F, Takeshima T, Tatsuoka Y, et al. A randomized Phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 59: 1731-1742, 2019.","DOI":"10.1111\/head.13652"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takeshima T, Sakai F, Hirata K, et al. Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61: 927-935, 2021.","DOI":"10.1111\/head.14138"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hirata K, Sakai F, Takeshima T, et al. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain 22: 110, 2021.","DOI":"10.1186\/s10194-021-01313-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang SJ, Roxas AA, Saravia B, et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study. Cephalalgia 41: 1285-1297, 2021.","DOI":"10.1177\/03331024211024160"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38: 1026-1037, 2018.","DOI":"10.1177\/0333102418759786"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yu S, Kim BK, Wang H, et al. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 23: 146, 2022.","DOI":"10.1186\/s10194-022-01514-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Barbanti P, Aurilia C, Egeo G, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in real life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61: 363-372, 2021.","DOI":"10.1111\/head.14032"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Becker WJ, Spacey S, Leroux E, et al. A real-world, observational study of erenumab for migraine prevention in Canadian patients. Headache 62: 522-529, 2022.","DOI":"10.1111\/head.14291"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Scheffler A, Messel O, Wurthmann S, et al. Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21: 84, 2020.","DOI":"10.1186\/s10194-020-01151-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Dinh BBK, Aziz WH, Terruzzi A, Krieger DW. Initial experience with novel CGRP-receptor inhibitor therapy in migraine in the United Arab Emirates: a retrospective observational study. BMC Neurol 21: 486, 2021.","DOI":"10.1186\/s12883-021-02507-y"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Belv\u00eds R, Irimia P, Pozo-Rosich P, et al. MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain 22: 74, 2021.","DOI":"10.1186\/s10194-021-01267-x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. de Vries Lentsch S, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real-life study. Eur J Neurol 28: 4194-4203, 2021.","DOI":"10.1111\/ene.15075"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Khalil M, Moreno-Ajona D, Villar-Mart\u00ednez MD, Greenwood F, Hoffmann J, Goadsby PJ. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol 29: 2473-2480, 2022.","DOI":"10.1111\/ene.15364"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lanteri-Minet M, Fabre R, Martin C, et al. One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study. J Headache Pain 24: 152, 2023.","DOI":"10.1186\/s10194-023-01680-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Hong JB, Lange KS, Fitzek M, et al. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany. J Headache Pain 24: 144, 2023.","DOI":"10.1186\/s10194-023-01682-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takizawa T, Ohtani S, Watanabe N, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22: 512, 2022.","DOI":"10.1186\/s12883-022-03041-1"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ohtani S, Watanabe N, Ihara K, et al. Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. BMC Neurol 23: 404, 2023.","DOI":"10.1186\/s12883-023-03449-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Suzuki K, Suzuki S, Shiina T, et al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia 43: 2023.","DOI":"10.1177\/03331024231177649"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Suzuki K, Suzuki S, Shiina T, et al. Real-world effectiveness of erenumab in Japanese patients with migraine. Heliyon 10: e26568, 2024.","DOI":"10.1016\/j.heliyon.2024.e26568"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Bolchini M, Schiano di Cola F, Ceccardi G, et al. Migraine disability and severity improvement during long-term treatment with erenumab. Eur Neurol 86: 135-139, 2023.","DOI":"10.1159\/000527674"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Straube A, Stude P, Gaul C, Schuh K, Koch M. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain 22: 133, 2021.","DOI":"10.1186\/s10194-021-01344-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Pathak P, Yue L, Gupta S, et al. Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey. Curr Med Res Opin 39: 1585-1591, 2023.","DOI":"10.1080\/03007995.2023.2191479"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ihara K, Ohtani S, Watanabe N, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain 24: 23, 2023.","DOI":"10.1186\/s10194-023-01556-7"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_4037-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:31:23Z","timestamp":1742009483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_4037-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4037-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"article-number":"4037-24"}}